- Healthcare Businesswomen’s Association: Women in Science – Winter 2011
- Interrelatedness of Alzheimer Pathways
- The Michael J. Fox Foundation for Parkinson’s Research: Therapeutics Development Initiative
- Alzheimer’s Rewind – October 24, 2011
- BioCentury – QR: Power of positivity – May 30, 2011
- ICAD Posiphen
- Mechanism of Action of Posiphen: from Model to Human
- Microglia Activation in the Alzheimer and Parkinson Brain; Normalization by Posiphen®
- Monoclonal Antibodies in Alzheimer�s – October 24, 2011
- NeuroScience Network – Is Alzheimer’s Disease Close To Being Cured? – May 11, 2010
- Oral Posiphen® Treatment Lowers Aß42 in Mouse Brain
- Philadelphia Business Journal – QR Pharma to start trial on Alzheimer’s drug – February 10, 2010
- Philadelphia Inquirer – On the Boards – June 8, 2009
- Posiphen Human Biomarker Data
- Posiphen Human Clinical Data
- Posiphen® Recovers Memory, Learning and Brain Function in Alzheimer Transgenic Mice M.L. Maccecchini, K. Sambamurti; J.T. Rogers, O. Arancio
- Posiphen® Technical Summary
- Posiphen® Treatment is Able to Reduce APP Levels in Ta65Dn Mouse Model of Down Syndrome
- Targeting Alzheimer’s and Other Neurodegenerative Diseases via a Novel Mechanism of Action
- Targeting Alzheimer’s with Novel Therapuetics
- Traumatic Brain Injury Increases Susceptibility to Alzheimer’s Disease
- WCBR Posiphen® Poster